Research map: Neoadjuvant immunotherapy followed by surgery versus non-operative management in dMMR/MSI gastroesophageal adenocarcinomas: a case series and review of the literature

Back to the article

Papers in this map

  1. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency · Dung Thi Le · 2015 · 9599 citations · Cited by this paper
  2. Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial · 2026 · Related
  3. Comprehensive molecular characterization of gastric adenocarcinoma · Adam Joel Bass · 2014 · 6688 citations · Cited by this paper
  4. Early-onset biliary tract cancers: clinical and molecular insights · 2026 · Related
  5. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer · David Cunningham · 2006 · 6432 citations · Cited by this paper
  6. Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer · 2026 · Related
  7. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial · Salah‐Eddin Al‐Batran · 2019 · 2702 citations · Cited by this paper
  8. A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE · 2026 · Related
  9. Integrated genomic characterization of oesophageal carcinoma · 2017 · 1911 citations · Cited by this paper
  10. Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study · 2026 · Related
  11. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer · Andrea Cercek · 2022 · 1659 citations · Cited by this paper
  12. Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study · 2026 · Related
  13. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Florian Lordick · 2022 · 1526 citations · Cited by this paper
  14. Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer · 2026 · Related
  15. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach · Claudio Luchini · 2019 · 1088 citations · Cited by this paper
  16. The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors · 2026 · Related
  17. Global burden of oesophageal and gastric cancer by histology and subsite in 2018 · Melina Arnold · 2020 · 644 citations · Cited by this paper
  18. BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer · 2026 · Related
  19. Complete Clinical Response After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer: Characterization of Clinical and Endoscopic Findings for Standardization · Angelita Habr‐Gama · 2010 · 456 citations · Cited by this paper
  20. Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands · 2026 · Related
  21. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study · Thierry André · 2022 · 410 citations · Cited by this paper
  22. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study · Bo Jan Noordman · 2018 · 340 citations · Cited by this paper
  23. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer · Yelena Yuriy Janjigian · 2025 · 319 citations · Cited by this paper
  24. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial · Sylvie Lorenzen · 2023 · 228 citations · Cited by this paper
  25. Nonoperative Management of Mismatch Repair–Deficient Tumors · Andrea Cercek · 2025 · 216 citations · Cited by this paper
  26. KEYNOTE-585: Phase III Study of Perioperative Chemotherapy with or Without Pembrolizumab for Gastric Cancer · Yung‐Jue Bang · 2019 · 176 citations · Cited by this paper
  27. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database · Edmund K. Bartlett · 2014 · 135 citations · Cited by this paper
  28. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO · A. Raimondi · 2024 · 95 citations · Cited by this paper
  29. Nonoperative Management of Rectal Cancer · Angelita Habr‐Gama · 2014 · 75 citations · Cited by this paper
  30. TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study · Alessandra Raimondi · 2021 · 53 citations · Cited by this paper
  31. Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study · Aziz Zaanan · 2025 · 36 citations · Cited by this paper
  32. The Duration of Immunotherapy for Mismatch Repair–Deficient Cancers · Benoı̂t Rousseau · 2025 · 31 citations · Cited by this paper
  33. Multimodality deep learning radiomics predicts pathological response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma · Yunsong Liu · 2024 · 24 citations · Cited by this paper
  34. Enhanced CT-based radiomics predicts pathological complete response after neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction: a two-center study · Wenpeng Huang · 2022 · 19 citations · Cited by this paper
  35. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II / III gastric cancer · Meng Zhang · 2023 · 19 citations · Cited by this paper
  36. Multi-cohort study in gastric cancer to develop CT-based radiomic models to predict pathological response to neoadjuvant immunotherapy · Ze‐Ning Huang · 2025 · 16 citations · Cited by this paper
  37. 1448P IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts · Christelle de la Fouchardière · 2024 · 15 citations · Cited by this paper
  38. Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis · Alessandra Raimondi · 2025 · 14 citations · Cited by this paper
  39. Circulating tumor DNA predicts recurrence and assesses prognosis in operable gastric cancer: A systematic review and meta-analysis · Junjie Mi · 2023 · 12 citations · Cited by this paper

Source: OpenAlex (CC0)